Poor
Not Aligned
Patient Risk:
High
Summary
The response contains many claims (mechanism, supplements, incidence/risk percentages, activity-specific timing, numeric risk multipliers, and specific risk-factor assertions) that are not supported by the provided FDA label sections. Only a minority of statements align with the label content shown (e.g., HMG-CoA reductase inhibition, general skeletal muscle/myopathy warnings and some interaction/dose-caution concepts).
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin drug for lowering cholesterol.
Supported by provided label excerpts: 12.1 Mechanism of Action; 1 INDICATIONS AND USAGE (lipid-altering agents adjunct; cholesterol-lowering context).
Statins block HMG-CoA reductase.
Supported by 12.1 Mechanism of Action (selective, competitive inhibitor of HMG-CoA reductase).
LIPITOR therapy should be discontinued if myopathy is diagnosed or suspected; therapy may be temporarily withheld/discontinued in acute serious conditions suggestive of myopathy/rhabdomyolysis risk.
Supported by 5.1 Skeletal Muscle (discontinue if markedly elevated CPK or myopathy diagnosed/suspected; temporarily withheld or discontinued in acute serious conditions suggestive of myopathy/risk of renal failure secondary to rhabdomyolysis).
Concomitant use with certain interacting drugs increases myopathy/rhabdomyolysis risk, and caution/dose limits are described for strong CYP3A4 inhibitors.
Supported by 5.1 Skeletal Muscle and 7.1 Strong Inhibitors of CYP 3A4 and related dosing cautions (e.g., caution when exceeding dose thresholds with clarithromycin/protease inhibitors/itraconazole).
Patients should be advised to report unexplained muscle pain, tenderness, or weakness promptly; risk is increased with certain medications and larger quantities of grapefruit juice (>1 liter).
Supported by 17.1 Muscle Pain.
Unsupported Statements
Muscle cramps and pain are known side effects of Lipitor (atorvastatin).
Label excerpt provided discusses 'myopathy' and skeletal muscle effects (muscle aches/weakness with CPK elevations) but does not specifically support the phrasing 'muscle cramps and pain' as labeled; partially supported at best (not clearly supported for 'cramps').
Muscle cramps and pain occur in 1-5% of users in clinical trials.
No numeric incidence is provided in the supplied label excerpts.
Muscle cramps and pain can occur suddenly during physical activity such as swimming.
No activity-specific timing/exposure (e.g., swimming) is stated in the supplied label excerpts.
Sudden muscle cramps during physical activity are attributed to statin-induced myopathy.
The label excerpt describes considering myopathy in patients with symptoms and CPK elevation, but does not attribute sudden, activity-specific cramps to statin-induced myopathy.
Statin-induced myopathy involves muscle inflammation or damage from impaired energy production in muscle cells.
No such mechanistic description is provided in the supplied label excerpts.
Statins reduce cholesterol but also deplete coenzyme Q10 (CoQ10).
CoQ10 depletion is not mentioned in the provided label excerpts.
CoQ10 is essential for muscle cell energy.
Not stated in the provided label excerpts.
Low CoQ10 levels can lead to cramps, weakness, or spasms.
Not stated in the provided label excerpts.
Cramps, weakness, or spasms occur especially in legs during exertion.
Not stated in the provided label excerpts.
Risk of statin-related cramps increases with older age.
Not stated in the provided label excerpts.
Risk of statin-related cramps increases with dehydration.
Not stated in the provided label excerpts.
No large studies isolate swimming as an exposure for cramps specifically with Lipitor.
This type of evidence statement is not supported by the provided label excerpts.
Patient reports describe sudden calf or thigh cramps mid-swim after starting Lipitor.
No patient-report or swimming-specific claim appears in the provided label excerpts.
Exercise intolerance, including cramps, occurs in 10-15% of statin users during aerobic activities.
No numeric prevalence is provided in the supplied label excerpts.
Swimming in chlorinated pools or sweat loss can deplete potassium and magnesium.
Not stated in the provided label excerpts.
Combining Lipitor with fibrates, antibiotics, or grapefruit juice increases myopathy risk by 5-10 fold.
The label excerpt supports increased risk with certain interacting drugs and provides grapefruit juice quantity caution, but no '5-10 fold' numeric multiplier is present in the provided label excerpts.
Hypothyroidism can heighten susceptibility to muscle symptoms.
Not stated in the provided label excerpts.
Vitamin D deficiency can heighten susceptibility to muscle symptoms.
Not stated in the provided label excerpts.
Sudden cramps warrant checking if accompanied by dark urine due to rhabdomyolysis risk.
The excerpt notes rhabdomyolysis with acute renal failure secondary to myoglobinuria, but does not provide the specific 'sudden cramps + dark urine checking' instruction.
The incidence of rhabdomyolysis is 0.01%.
No incidence figure is provided in the supplied label excerpts.
Doctors may switch statins when concerning muscle symptoms occur.
The provided label excerpt says discontinue/withhold in certain situations but does not state 'switching to another statin' as a labeled management step.
CoQ10 supplements (100-200 mg/day) ease symptoms in some people per small trials.
No CoQ10 supplement dosing or efficacy claims appear in the provided label excerpts.
Switching to rosuvastatin (Crestor) is an alternative option.
No rosuvastatin-specific alternative is stated in the provided label excerpts.
Rosuvastatin has fewer muscle reports than other statins (as stated).
No comparative rosuvastatin reporting statement appears in the provided label excerpts.
Non-statins like ezetimibe/PCSK9 inhibitors are alternatives.
No non-statin alternative options are stated in the provided label excerpts.
Lowering statin dose can be an alternative if Lipitor is the suspected cause.
The provided label excerpt supports dose adjustments in the setting of interacting drugs, but does not broadly endorse dose reduction as a general alternative for suspected atorvastatin-related symptoms.
Contradictions
Important Omissions
The label excerpt emphasizes myopathy definition (muscle aches/weakness with CPK >10 times ULN) and that LIPITOR should be discontinued if markedly elevated CPK occurs or myopathy is diagnosed/suspected; the response does not clearly include the CPK threshold/myopathy definition.
Importance:
Moderate
The label excerpt discusses specific risk-factor predisposing to renal failure secondary to rhabdomyolysis (e.g., severe acute infection, hypotension, major surgery, trauma, severe metabolic/endocrine/electrolyte disorders, uncontrolled seizures) for temporarily withholding/discontinuing; the response instead adds several unlabel-supported risk factors (age, dehydration, hypothyroidism, vitamin D deficiency) without label support.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Many claims provide unsupported numeric incidence/risk multipliers and mechanism/supplement guidance not present in the provided label excerpts, which could misinform monitoring and management. Some label-consistent safety advice is present (report muscle symptoms; discontinue/withhold in myopathy/rhabdomyolysis-suggestive conditions; caution with interacting drugs), but unsupported sections significantly reduce on-label fidelity.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Substantial number of mechanism, numeric incidence/risk statements, and activity- and supplement-specific claims are not supported by the provided FDA label excerpts.
Suggested Improvement
Restrict claims to label-supported concepts from provided sections: general myopathy/rhabdomyolysis warning (including CPK >10x ULN definition), advise prompt reporting of unexplained muscle pain/tenderness/weakness, label-supported drug interaction risk with strong CYP3A4 inhibitors/fibric acid derivatives and grapefruit juice quantity (>1.2 L/day or >1 liter/day per excerpt), and label-supported management (withhold/discontinue in acute serious myopathy-suggestive conditions; discontinue if myopathy diagnosed/suspected). Remove CoQ10 depletion/supplement efficacy, all swimming-specific and numeric incidence/risk-multiplier claims, and all unlabel-supported risk-factor assertions.